Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography.
about
Potential role of thrombelastography in the monitoring of acquired factor VIII inhibitor hemophilia A: report on a 78-year-old woman with life-threatening bleedings.Rotation thromboelastometry analysis of clot formation and fibrinolysis in severe thrombocytopenia: effect of fibrinogen, activated prothrombin complex concentrate, and thrombin- activatable fibrinolysis inhibitor.Haemophilia therapies.Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives.Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience.Inhibitor development in haemophilia B: an orphan disease in need of attention.Biomechanics of haemostasis and thrombosis in health and disease: from the macro- to molecular scaleThrombin generation testing in haemophilia comprehensive care centres.When should prophylaxis therapy in inhibitor patients be considered?The use of a single von Willebrand factor-containing, plasma-derived FVIII product in hemophilia A immune tolerance induction: the US experience.Parallel use of by-passing agents in haemophilia with inhibitors: a critical review.How we use recombinant activated Factor VII in patients with haemophilia A or B complicated by inhibitors. Working group of hematology experts from Australia and New Zealand, Melbourne, April 2011.Sequential therapy with activated prothrombin complex concentrates and recombinant activated factor VII to treat unresponsive bleeding in patients with hemophilia and inhibitors: a single center experience.Global coagulation assays: a clinical perspective.The pharmacokinetics and pharmacodynamics of single-dose and multiple-dose recombinant activated factor VII in patients with haemophilia A or B.The utility of thromboelastography in inherited and acquired bleeding disorders.Systematic monitoring of hemostatic management in hemophilia A patients with inhibitor in the perioperative period using rotational thromboelastometry.The efficacy of bypassing agents in surgery of hemophilia patients with inhibitors.Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of hemophilia.Experience with a single dose of recombinant activated factor VII for the management of mild-to-moderate bleeds in haemophilia.Case studies in the management of refractory bleeding in patients with haemophilia A and inhibitors.Treatment of refractory hemorrhage with Factor XIII in a patient with hemophilia A with inhibitor.Evaluation of the overall haemostatic effect of recombinant factor VIIa by measuring thrombin generation and stability of fibrin clots.Evaluation of the use of global haemostasis assays to monitor treatment in factor XI deficiency.Evaluation of the use of rotational thromboelastometry in the assessment of FXI deficiency.Standardization of thromboelastography: a report from the TEG-ROTEM working group.Monitoring bypassing agent therapy - a prospective crossover study comparing thromboelastometry and thrombin generation assay.On-demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VII.Feasibility of using thrombin generation assay (TGA) for monitoring bypassing agent therapy in patients with hemophilia having inhibitors.Retrospective evaluation of bleeding tendency and simultaneous thrombin and plasmin generation in patients with rare bleeding disorders.Global haemostasis and point of care testing.Combined administration of FVIII and rFVIIa improves haemostasis in haemophilia A patients with high-responding inhibitors--a thrombin generation-guided pilot study.Bypass therapy assay testing as a strategy to reduce costs for treatment of haemophilia patients with inhibitors.
P2860
Q33156750-2C332032-7CD2-412E-8B6A-908609EC1F61Q33420178-3C22D045-32E7-453C-BB14-38A4686846FAQ36810282-BB6CA632-7B0A-4C6E-A4ED-A0AEA1A591B0Q36818527-0443AFE5-E9B0-4F17-AD11-74B0432EBDC0Q36819965-4F7E06FF-E312-4C36-97DB-0FBA16621C55Q36872038-5AD9A467-6431-4B32-BB66-F8151496B483Q37294541-0EBA4018-461E-4B78-B844-8DA3EA38E3CEQ37589662-70872132-CAA4-4E3A-B80A-032E27803082Q37854874-F6509AC5-2E6C-4199-95F2-1F8FFCEC36DBQ37924970-5D69367C-5B56-4030-AE98-1F480BE50A59Q37927122-DBA83083-9DA7-4B37-A682-0D8C969424E1Q38060224-22DB215C-1010-4ED1-A8D4-99DC2D326912Q38182105-CEB0184C-D133-4026-91C0-27669317963BQ38253173-90B5A4B0-F914-45FD-A536-EEE2D21FABBAQ38603559-EB160548-5B51-4752-BDE8-E9DAE3DE785BQ38855599-2691D1E2-C2F7-4BAF-A356-28E04C72DF41Q41026811-9ADDEB21-B739-4A7B-803E-A0EC34378EE1Q41210614-EA05B43A-B4E0-4871-93B4-3C752C323FA6Q42360054-393D139B-6A70-4E9C-9D17-8CC5197C50C4Q42722916-CF1031B5-2C18-40D7-AFE7-4651F72CBBB2Q44211358-2E3CE993-3848-42E8-9A62-1A7962AB7AA1Q44251818-167965A2-0F33-4FB4-848C-AC0C02535D9DQ45168592-D5BB7BA5-49DF-4AF6-8D55-4B3D0B4CC3D4Q45861959-6F6DC024-5AD3-4A29-A150-50D95342BCF8Q45863678-DAE30AB7-CC29-400D-B4DD-2B97847142CCQ45867256-D125F074-FF25-4854-8DD8-B89DF2F33D70Q45871315-5B36E425-DE10-4651-BE5C-EDAE497CBF21Q45871901-35AE2E72-5374-4205-A9D0-4365032FB61DQ45877685-757E0632-2832-4812-990B-6D02964291EFQ45877770-1D1FD8FD-B755-47D7-8D86-75B67546ADE6Q45879939-2F475826-65C1-42F0-B3F4-6000EFC2664FQ45887437-E22E8603-973E-4961-99C9-336923642649Q45887517-FEAADAB4-420F-4178-8A89-93F0C52A588A
P2860
Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Individualization of bypassing ...... utilizing thromboelastography.
@en
Individualization of bypassing ...... utilizing thromboelastography.
@nl
type
label
Individualization of bypassing ...... utilizing thromboelastography.
@en
Individualization of bypassing ...... utilizing thromboelastography.
@nl
prefLabel
Individualization of bypassing ...... utilizing thromboelastography.
@en
Individualization of bypassing ...... utilizing thromboelastography.
@nl
P2093
P2860
P1433
P1476
Individualization of bypassing ...... utilizing thromboelastography.
@en
P2093
P2860
P304
P356
10.1111/J.1365-2516.2006.01319.X
P50
P577
2006-11-01T00:00:00Z